Unlike in EOMG, more than 80% of patients with thymomas have autoantibodies against striational antigens, such as titin and ryanodine receptors (RYRs), as well as others that neutralize cytokines, including type I interferon (IFN) and IL-12 (110, 111). Here, TTN is linked to thymoma.